Hepatic sinusoidal obstructive syndrome (SOS), also known as hepatic veno-occlusive disease (VOD), is recognized as one of the most important regimen-related toxicities experienced after hematopoietic stem cell transplantation (SCT). It is a clinical syndrome characterized by painful hepatomegaly, jaundice, ascites, fluid retension, and weight gain [1]. Across 135 studies between 1979 and 2007, the overall incidence was 13.7% in patients undergoing SCT [2], and it usually occurs within the first 3 weeks after high-dose chemotherapy followed by SCT [3]. Severity ranges from mild, reversible disease to a severe syndrome associated with multiorgan failure [4].